

Emtricitabine + tenofovir



Essential medicine status ✓

Section: [6. Anti-infective medicines](#) > [6.4. Antiviral medicines](#) > [6.4.2. Antiretrovirals](#) > [6.4.2.5. Fixed-dose combinations of antiretrovirals](#)

ATC codes: **J05AR03**

Indication	Contact with or exposure to human immunodeficiency virus	ICD11 code: QC90.6
INN	Emtricitabine + tenofovir	
Medicine type	Chemical agent	
List type	Core	
Formulations	Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	
EML status history	First added in 2017 (TRS 1006) Changed in 2021 (TRS 1035)	
Sex	All	
Age	Adolescents and adults	
Therapeutic alternatives	lamivudine + tenofovir (ATC codes: J05AR12)	
Patent information	Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org Read more about patents.	
Wikipedia	Emtricitabine + tenofovir	
DrugBank	Emtricitabine , Tenofovir (Tenofovir disoproxil)	

Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended lamivudine be specified as a therapeutic alternative for the emtricitabine component under the square box listing for emtricitabine + tenofovir on the EML.

